Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma (clinicaltrials.gov) - Oct 20, 2026 - P1/2 | N=28 | Recruiting | Sponsor: John Kirkwood | Not yet recruiting ➔ Recruiting
Enrollment open • First-in-human • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor
|